当前位置: 首页 > 期刊 > 《健康周刊》 > 201818
编号:13586184
莫西沙星治疗初治肺结核的近期疗效(3)
http://www.100md.com 2018年5月7日 《健康周刊》 201818
     [8]Farhat MR,Jacobson KR,Franke MF,et al.Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study[J].Clin Infect Dis,2017,65(8):1364-1370.

    [9]刘智,傅佳鹏,杨梁梓,等.左氧氟沙星和莫西沙星治疗耐多药肺结核临床疗效比较[J].临床肺科杂志,2017,22(4):711-714.

    [10]Heinrichs MT,Vashakidze S,Nikolaishvili K,et al.Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study[J].J Antimicrob Chemother, 2018,73(2):477-483.

    [11]韓平.莫西沙星联合卷曲霉素治疗耐多药肺结核的疗效及对免疫功能、肝功能的影响[J].河北医药,2018,40(6):925-927.

    [12]张劲,腾丹华,张天,等.中药联合莫西沙星治疗耐多药肺结核患者疗效及对免疫功能的影响[J].现代中西医结合杂志,2017,26(6):650- 652.

    [13]Penn-Nicholson A,Tameris M,Smit E,et al.Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial[J].Lancet Respir Med,2018,6(4):287-298.

    [14]Azaev MSh,Agafonov AP,Bodnev SA,et al.Study of antituberculous activity of moxifloxacin conjugate with macrophage scavenger-receptor ligand[J].Antibiot Khimioter,2006,51(11-12):7-10., http://www.100md.com(孙婷婷 郭春辉 翁锡定 陈建新)
上一页1 2 3